Fees may help ease generics regulation; Oklahoma tries alternative execution drug;

> Generics-makers could enjoy fewer plant inspections and a streamlined drug approval process in exchange for paying fees to the FDA. Article

> Given Hospira's ongoing shortage of sodium thiopental, Oklahoma prison officials have turned to pentobarbital, used in the veterinary euthanization, as the first component of its lethal injection. Article

> Pfizer is recalling an additional lot (19,000 bottles) of Lipitor following another customer report of a packaging odor. Story

> Antitrust regulators have cleared Cardinal Health's $1.3 billion takeover of Kinray, a distributor specializing in independent retail pharmacies in the northeastern U.S. Article

> BeneLein will test the commercial feasibility of a top 10 pharma's process for manufacturing a key antibiotic product. BeneLein release

> Pristine Pharma, a subsidiary of Michelex, plans to begin production of cough syrups and other liquid OTC medicines in a new 30,000-sq. ft facility in Massena, NY, in February. Michelex announcement

> Novartis plans to build a full-scale pharmaceutical manufacturing plant in St Petersburg, Russia. News | Story

> The U.K.'s Merck BioManufacturing Network will produce the large-scale GMP clinical and pre-commercial supplies of A-623, an investigational novel peptibody being developed by Anthera Pharmaceuticals. Anthera announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.